State Street's passive stake increase is routine for a large index fund manager and does not signal activist intent. Monitor the next 13F filing for any material changes in institutional positioning, but no immediate catalyst from this filing alone.
ACAD drugs
ACAD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $18.28entry
- T+1 · 6d ago +0.49%α −0.83% · $18.37
- T+4 · todayOpen
- T+5 · in 5h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corporation filed a Schedule 13G disclosing a 4.4% passive stake in Acadia Pharmaceuticals as of September 30, 2026, with 7,650,889 shares held. This is an amendment to its prior 13G filing from August 2026, showing a slight increase in share count. The filing confirms a passive investment intent with no activist purpose.
Key Financial Metrics
Key Facts
- State Street Corporation disclosed beneficial ownership of 7,650,889 shares of ACADIA PHARMACEUTICALS INC common stock as of September 30, 2026.
- The stake represents 4.4% of shares outstanding.
- The filing is an amendment to a prior Schedule 13G filed on August 7, 2026.
- State Street certifies the securities were acquired and are held in the ordinary course of business, not for changing or influencing control.
- The filing is made under Rule 13d-1(b), confirming passive investor status.
Financial Impact
State Street's stake of 7,650,889 shares at a market cap of $3.7B implies a value of approximately $162.8M (4.4% of $3.7B).
Risk Factors
- No material risks identified from this passive stake filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000603 |
| Document: 0000093751-26-000603-index.html | 0000093751-26-000603 |
| Document: 0000093751-26-000603.txt | 0000093751-26-000603 |
Track record
14 reports on ACAD
1 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +5.01% at T+20 after the May 6, 2026 report. 2 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $18.28 Now $18.67 +2.13% settles Dec 9
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $21.24 Now $18.67 −12.10% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $20.57 Now $18.67 −9.24% settles Dec 2
- Oct 23, 202624d ago 8-K Neutral 3/10 Entry $19.74 Now $18.67 −5.42% settles Nov 23
- Sep 24, 20267w ago 8-K Bullish 6/10 Entry $20.68 to $19.73 Now $18.67 −9.72% ▼ −4.59% −3.12% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $27.52 to $19.41 Now $18.67 −32.16% ▼ −29.47% −31.73% vs SPY
- Aug 16, 202613w ago Institutional Cluster Mixed 5/10 Entry $29.01 to $26.76 Now $18.67 −35.64% ▼ −7.76% −5.78% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $29.39 to $27.58 Now $18.67 −36.47% ▼ −6.16% −5.24% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $21.39 to $26.41 Now $18.67 +12.72% ▼ −23.47% −21.58% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Entry $22.56 to $21.43 Now $18.67 +17.24% ▲ +5.01% +8.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers